Tumor necrosis factor augments the immunogenicity and the production of L-ornithine by peritoneal macrophages.
The release of ornithine by macrophages and its correlation with their immunogenicity after treatment with recombinant human tumor necrosis factor-alpha (TNF) were analyzed. TNF was found to augment the capacity of peritoneal macrophages to convert 14C-labeled arginine into L-ornithine and to release L-ornithine into the culture medium. In agreement with the previous observation that L-ornithine potentiates immune responses in vivo, it was also found that treatment of peritoneal exudate cells with TNF augments the capacity of these cells to immunize mice in vivo for a subsequent secondary in vitro cytotoxic response against non-major-histocompatibility antigens.
D000818:Animals; D001120:Arginine / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D006023:Glycoproteins / Q000494:pharmacology*; D007114:Immunization; D066298:In Vitro Techniques; D008262:Macrophage Activation; D008264:Macrophages / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D009952:Ornithine / Q000096:biosynthesis*; D014409:Tumor Necrosis Factor-alpha
D006023:Glycoproteins; D014409:Tumor Necrosis Factor-alpha; D001120:Arginine; D009952:Ornithine